Company intelligence / Profile preview

Tilikum Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Tilikum Therapeutics has developed a novel class of PARP-locking small molecule inhibitors that show strong cytotoxicity against cancer cells at low doses. Unlike conventional PARP inhibitors that require pre-existing DNA repair defects in tumors, Tilikum’s compounds are active even in tumors without such defects or those with acquired resistance. Their lead compound ("TLK001", also referred to as "Pip6") has demonstrated promising preclinical efficacy and will be profiled in upcoming Phase 1A/B trials targeting high-replicative stress tumor populations.

Therapeutic areas: Oncology
Modalities: Small molecules (PARP1 inhibitors)Antibody-drug conjugates (ADC-delivered small molecules)
Industry: Biotech

Partnerships

Oregon Health & Science University (OHSU) – exclusive option/license for core technologyActively seeking investment/collaboration opportunities; no major pharma partnerships publicly disclosed yet

Beyond the preview

Go deeper on Tilikum Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tilikum Therapeutics.

Explore the full profile